CMAB007
Phase 3Biologic
CMAB007 is one of 77 biologic programs targeting Allergic Asthma. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
66 competitors in Allergic Asthma
#DrugCompanyPhaseTrials
1Xolair
RochePhase 3
Xolair
RochePhase 3
Symbicort
AstraZenecaPhase 3
Levocetirizine Dihydrochloride
UCBPhase 3
Tezspire
AstraZenecaPhase 2
Daliresp
AstraZenecaPhase 2
Soliris
AstraZenecaPhase 2
EBGLYSS
Eli LillyPhase 2
Inhaled Corticosteroids
Boehringer IngelheimApproved
C1-Inhibitor
UUniversitaire Ziekenhuizen KU Leuven
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity1 trial
Chronic Spontaneous Urticaria1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CMAB007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details